ERN1 and metabolic dysfunction-associated steatotic liver disease: Studies indicate that ERN1 activation is associated with hepatocyte steatosis and inflammatory responses, suggesting its potential as a therapeutic target in NAFLD progression (Lebeaupin et al., 2018).